MiMedx Group (MDXG) Financials: History & Chart

MiMedx Group, Inc.(MDXG)

Biotechnology · Marietta, GA

$4.58+0.03 (+0.55%)

Delayed quote: Oct 6, 2026, 3:40 PM EDT

About MiMedx Group, Inc.

MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.

Marietta, GA

808 employees

www.mimedx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joseph H. Capper

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	355.17M	64.36M	58.99M	118.09M	113.72M	98.61M	88.20M	92.91M	84.06M
Cost of Goods Sold	75.12M	19.98M	17.37M	19.05M	18.72M	18.68M	16.56M	16.91M	15.32M
Gross Profit	280.05M	44.38M	41.62M	99.04M	95.01M	79.92M	71.65M	76.00M	68.73M
Gross Profit Margin	78.8%	69.0%	70.6%	83.9%	83.5%	81.1%	81.2%	81.8%	81.8%
Total Operating Expenses	271.17M	62.85M	57.67M	77.84M	72.82M	67.55M	63.40M	64.94M	57.57M
Research & Development	15.38M	2.78M	4.14M	4.76M	3.70M	3.30M	3.33M	3.57M	2.92M
Selling, General & Administrative	255.08M	59.78M	53.23M	73.07M	69.00M	64.15M	59.97M	61.09M	54.16M
Operating Income (EBIT)	8.75M	-18.47M	-16.05M	21.08M	22.19M	12.37M	8.25M	11.05M	11.16M
Operating Margin	2.5%	-28.7%	-27.2%	17.8%	19.5%	12.5%	9.4%	11.9%	13.3%
Income Before Tax (EBT)	11.53M	-17.78M	-15.33M	21.80M	22.85M	13.01M	8.61M	11.25M	11.42M
Interest Income	2.60M	N/A	1.29M	1.31M	N/A	1.21M	984K	2.93M	278K
Interest Expense	1.59M	N/A	402K	405K	785K	475K	478K	2.53M	N/A
Other Income/Expense	2.78M	686K	718K	718K	659K	637K	361K	195K	257K
Net Income	6.24M	-14.84M	-10.86M	15.19M	16.75M	9.62M	7.02M	7.44M	8.10M
Income Tax Expense	5.29M	-2.94M	-4.47M	6.61M	6.10M	3.39M	1.59M	3.81M	3.54M
Net Profit Margin	1.8%	-23.1%	-18.4%	12.9%	14.7%	9.8%	8.0%	8.0%	9.6%
EBITDA	20.41M	-16.93M	-14.43M	24.30M	27.48M	15.51M	11.48M	14.04M	12.32M
EBITDA Margin	5.7%	-26.3%	-24.5%	20.6%	24.2%	15.7%	13.0%	15.1%	14.7%
Depreciation & Amortization	11.66M	1.53M	1.62M	3.22M	5.29M	3.14M	3.23M	2.99M	1.16M
EPS Basic	0.04	-0.10	-0.07	0.10	0.11	0.07	0.05	0.05	0.06
EPS Diluted	0.04	-0.10	-0.07	0.10	0.11	0.06	0.05	0.05	0.05
Weighted Average Basic Shares	147.80M	147.80M	148.45M	147.79M	148.04M	147.76M	147.27M	146.98M	146.96M
Weighted Average Diluted Shares	147.80M	147.80M	148.45M	149.72M	149.71M	149.32M	149.68M	149.05M	148.37M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	418.63M	348.88M	321.48M	267.84M	242.02M	248.23M	299.25M	359.11M
Cost of Goods Sold	73.01M	60.07M	54.63M	48.32M	39.63M	39.33M	43.08M	36.39M
Gross Profit	345.62M	288.81M	266.84M	219.53M	202.39M	208.90M	256.17M	322.73M
Gross Profit Margin	82.6%	82.8%	83.0%	82.0%	83.6%	84.2%	85.6%	89.9%
Total Operating Expenses	281.29M	229.94M	229.73M	234.25M	209.44M	254.30M	277.33M	326.65M
Research & Development	15.10M	12.34M	12.66M	12.70M	9.93M	11.71M	11.14M	15.77M
Selling, General & Administrative	266.19M	216.39M	216.30M	220.85M	194.85M	240.49M	264.71M	295.25M
Operating Income (EBIT)	63.89M	58.87M	37.12M	-14.73M	-7.05M	-45.40M	-21.16M	-3.92M
Operating Margin	15.3%	16.9%	11.5%	-5.5%	-2.9%	-18.3%	-7.1%	-1.1%
Income Before Tax (EBT)	66.26M	57.29M	30.63M	-19.75M	-12.05M	-61.54M	-25.59M	-3.40M
Interest Income	4.72M	N/A	N/A	N/A	N/A	N/A	N/A	527K
Interest Expense	1.78M	1.01M	6.46M	5.02M	4.98M	7.94M	4.71M	N/A
Other Income/Expense	2.38M	-1.57M	-6.48M	-5.02M	-5.00M	-16.14M	-4.42M	527K
Net Income	48.58M	42.42M	67.44M	-30.20M	-12.30M	-49.28M	-25.58M	-29.98M
Income Tax Expense	17.68M	15.30M	-36.81M	206K	247K	-12.26M	-5K	26.58M
Net Profit Margin	11.6%	12.2%	21.0%	-11.3%	-5.1%	-19.9%	-8.5%	-8.3%
EBITDA	78.77M	64.91M	40.54M	-10.68M	-1.87M	-38.54M	-13.57M	2.99M
EBITDA Margin	18.8%	18.6%	12.6%	-4.0%	-0.8%	-15.5%	-4.5%	0.8%
Depreciation & Amortization	14.88M	6.04M	3.43M	4.05M	5.18M	6.86M	7.58M	6.92M
EPS Basic	0.33	0.29	0.48	-0.27	-0.09	-0.46	-0.24	-0.28
EPS Diluted	0.32	0.28	0.38	-0.27	-0.09	-0.46	-0.24	-0.28
Weighted Average Basic Shares	147.79M	146.98M	116.50M	112.91M	110.35M	108.26M	106.95M	105.60M
Weighted Average Diluted Shares	149.72M	149.05M	145.96M	112.91M	110.35M	108.26M	106.95M	105.60M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.